Has filgotinib been approved for use in China?

Filgotinib(Filgotinib) has not yet been approved for use by the National Medical Products Administration (NMPA) of China, and the original drug has not been officially launched in China, so it has not yet been included in the medical insurance list. This means that the drug cannot be purchased and used through formal channels in mainland China. Patients who need such treatment often need to obtain it through cross-border medical treatment or other special channels. In addition, because it is not marketed in China, the domestic pricing of filgotinib is not yet clear, and it cannot enjoy the support of medical insurance reimbursement policies.

In the overseas market, filgotinib has been approved for marketing in many European countries. Its main indications are patients with moderate to severe active rheumatoid arthritis, especially those who have poor treatment effects with traditional DMARDs. Because it has relatively higher JAK1 selectivity, it may reduce the safety concerns related to some JAK inhibitors to a certain extent, so it has received a certain degree of recognition internationally. Its launch further enriches the selection of targeted drugs in the field of immune disease treatment, and also provides alternatives for some patients whose traditional treatment methods are not effective.

In China, although it has not yet been approved, with the increasing domestic attention to new targeted immunomodulators and the country's gradual opening up to the introduction of new drugs, it can be expected that filgotinib may be introduced into the Chinese market in the future. Its listing process is affected by many factors, including drug registration application, clinical data review, economic evaluation, etc. Once it is launched and included in medical insurance, its clinical accessibility may be significantly improved. For patients with urgent medication needs, it is recommended to evaluate alternative drug options or participate in related treatments through clinical trial channels under the guidance of professional doctors. Do not purchase drugs across borders on your own to avoid medication safety risks.

Reference materials:https://go.drugbank.com/drugs/DB14845